The companies will work collaboratively toward the submission for regulatory approval of an in vitro diagnostic product which is used to detect fetal chromosomal abnormalities.
Sequenom chairman and CEO Harry Hixson said this agreement brings trisomy test to market, gives us the scalability to address the opportunity of their noninvasive prenatal test for trisomy 21.
Illumina president and CEO Jay Flatley with the sequencing technology available, they are ready to meet Sequenom’s needs as it prepares for the commercial launch of test.
